Hereditary neuropathy: causes, symptoms, diagnosis, and modern approaches to treatment

[108]

The best-known and most common form of hereditary neuropathy is Charcot-Marie-Tooth disease. However, the topic is much broader, as dozens of clinical subtypes and a very large number of genes have been described today, the disruption of which can lead to similar symptoms of weakness, foot deformities, numbness, pain, balance disorders, and autonomic dysfunction. In 2024-2025, reviews and genetic studies emphasize that the spectrum of hereditary neuropathies is expanding, and the boundaries between "classic" and complex, multisystem variants are becoming less rigid. [2]

Most importantly, hereditary neuropathy often develops slowly and can be perceived for years as "clumsiness," "weak legs," "poor posture," "frequent ankle rolls," or "hereditary gait characteristics." Because of this, patients often have a long road to a proper diagnosis. A modern approach requires not only electromyography and nerve conduction studies but also a well-designed genetic algorithm, as molecular confirmation is increasingly influencing prognosis, family monitoring, and, for some subtypes, the choice of targeted therapy. [3]

A particular reason for interest in this topic is that for most hereditary neuropathies, treatment remains primarily supportive, but for some forms, more targeted approaches have already emerged or are actively being developed. The most prominent example is hereditary transthyretin amyloidosis with polyneuropathy, where gene-targeted drugs and protein stabilizers are used. For Charcot-Marie-Tooth disease and related conditions, clinical trials of targeted molecules and methods to reduce the toxic effects of pathological genes are also ongoing. [4]

From a scientific perspective, hereditary neuropathy is a good example of how a single clinical complaint can conceal very different disease mechanisms. In one patient, the primary symptom will be demyelination, that is, damage to the myelin sheath of the nerve. In another, it will be axonal degeneration, when the long nerve cell itself is damaged. In a third, it will be the deposition of a pathological protein, toxic to peripheral nerves and internal organs. Therefore, a modern article on this topic must explain not only the symptoms but also the differences between the forms of the disease. [5]

What is important to know right away	Brief explanation
What is this?	A group of genetic diseases of the peripheral nerves
What nerves can be affected?	Motor, sensory, vegetative
The most common form	Charcot-Marie-Tooth disease
Why is diagnosis often delayed?	Slow progression and wide clinical variability
What has changed in recent years	Advanced genetic testing has become more accessible, and targeted methods for specific subtypes have become available.

Source for the table. [6]

Code according to ICD 10 and ICD 11

There is no single, universal, and equally accurate code for "hereditary neuropathy" that covers the entire spectrum of diseases. The International Classification of Diseases, 10th revision, uses block G60 - hereditary and idiopathic neuropathies, within which are separate categories for hereditary motor and sensory neuropathy, Refsum disease, neuropathy in hereditary ataxia, other hereditary neuropathies, and unspecified variants. In practice, G60.0 - hereditary motor and sensory neuropathy - is most often used for classic forms such as Charcot-Marie-Tooth disease, but for other subtypes, the code depends on the specific disease. [7]

The International Classification of Diseases, 11th revision, has expanded its coding. Hereditary neuropathies now have a separate section with the headings 8C20 (hereditary motor and sensory neuropathy), 8C21 (hereditary sensory or autonomic neuropathy), 8C2Y (other specified hereditary neuropathy), and 8C2Z (hereditary neuropathy, unspecified). This better reflects the current understanding that a common clinical umbrella encompasses different diseases with different mechanisms. [8]

Individual subtypes are coded even more precisely. For example, in the International Classification of Diseases, 11th revision, Charcot-Marie-Tooth demyelinating disease has the subcategory 8C20.0, axonal demyelinating disease has the subcategory 8C20.1, and intermediate demyelinating disease has the subcategory 8C20.2. This is important for medical records, scientific registries, and statistics, but in clinical practice, the key is not the formal code, but precise molecular and phenotypic verification. [9]

If the diagnosis has not yet been confirmed genetically, coding often begins with a broader category. Once a specific form is confirmed, it can be revised.

Classification	Code	What does it mean?
ICD 10	G60	Hereditary and idiopathic neuropathies
ICD 10	G60.0	Hereditary motor and sensory neuropathy
ICD 10	G60.8	Other hereditary and idiopathic neuropathies
ICD 10	G60.9	Unspecified hereditary and idiopathic neuropathy
ICD 11	8C20	Hereditary motor and sensory neuropathy
ICD 11	8C21	Hereditary sensory or autonomic neuropathy
ICD 11	8C2Y	Other specified hereditary neuropathy
ICD 11	8C2Z	Hereditary neuropathy, unspecified

Source for the table. [10]

Epidemiology

The precise epidemiology of hereditary neuropathies as a whole is difficult to determine because they are not a single disease but a genetically and clinically highly heterogeneous group. However, reviews indicate that the overall prevalence of hereditary peripheral neuropathies is approximately 1 in 2,500 people, making this group one of the most common among hereditary neurological diseases. [11]

The most common form is Charcot-Marie-Tooth disease. More recent reviews cite a broad prevalence range for this group, ranging from approximately 9.7 to 82 cases per 100,000 population, due to different study designs, varying availability of genetic testing, and uneven coverage of mild, asymptomatic forms. Therefore, in a practical article, it is more appropriate to emphasize not a single "ideal" number, but rather the existence of a range and the risk of underdiagnosis. [12]

Hereditary neuropathy with susceptibility to compression palsies is less common, but also likely underdiagnosed. Orphanet estimates the prevalence at 1-9 cases per 100,000, while other sources emphasize that the actual incidence may be higher due to mild or atypical manifestations. This form is often misdiagnosed as carpal tunnel syndromes, episodic mononeuropathies, and the consequences of minor nerve compression. [13]

Hereditary sensory and autonomic neuropathies are significantly less common and are explicitly described as rare in some guidelines. For some subtypes, the frequency is known only in specific populations or families. In practice, this means that the epidemiological significance of this group is determined primarily by Charcot-Marie-Tooth disease and related motor-sensory forms, while rare sensory, autonomic, and complex syndromic variants require specialized investigation. [14]

Age bias is another issue worth keeping in mind. Although many hereditary neuropathies begin in childhood or adolescence, some forms appear in adulthood, and some patients remain undiagnosed for long periods. Recent molecular diagnostic studies show that a hereditary cause can be detected even in patients over 50, especially if the diagnosis was previously considered acquired. [15]

Epidemiological indicator	What is known
Cumulative prevalence of hereditary peripheral neuropathies	About 1 in 2500
The most common form	Charcot-Marie-Tooth disease
Estimation of the prevalence of Charcot-Marie-Tooth disease	Approximately 9.7-82 per 100,000
Estimation of the prevalence of neuropathy with susceptibility to compression palsies	Approximately 1-9 per 100,000
The main epidemiological problem	Underdiagnosis of mild and late-manifesting forms

Source for the table. [16]

Reasons

The cause of hereditary neuropathy is always a genetic defect, but the defects themselves can be very diverse. The disease can arise from a point mutation, deletion, duplication, gene copy number imbalance, mitochondrial protein defect, or accumulation of abnormal proteins. Current reviews emphasize that the number of genes associated with hereditary polyneuropathy is already very large and continues to grow. [17]

For classic hereditary motor-sensory neuropathies, the most well-known genes are PMP22, MFN2, MPZ, GJB1, and several others. In Charcot-Marie-Tooth disease type 1, duplication of the region containing the peripheral myelin protein 22 gene, designated PMP22, explains the majority of cases. In axonal forms, the MFN2 gene, encoding mitofusin 2, is often involved. In some subtypes, the disease is inherited in an autosomal dominant manner, while in others it is autosomal recessive or X-linked. [18]

For hereditary neuropathy with susceptibility to compression palsies, the underlying cause is most often a deletion of PMP22, and less commonly, pathogenic variants in the same gene. This is a typical example of how the same gene with different copy numbers can produce different phenotypes: excess protein is more often associated with Charcot-Marie-Tooth disease type 1A, while deficiency is associated with neuropathy predisposed to compression palsies. [19]

There is also a special class of hereditary neuropathies, where the primary mechanism is not a myelin defect or primary axonopathy, but the deposition of abnormal protein. The most clinically important example is hereditary transthyretin amyloidosis, in which mutations in the TTR gene lead to the formation of an unstable transthyretin protein with amyloid deposition in nerves and internal organs. This form is particularly important because targeted treatment options exist for it. [20]

Some hereditary neuropathies are part of more complex multisystem diseases. Merck explicitly states that hereditary neuropathies can be primary or secondary to other hereditary disorders, including Refsum disease, porphyrias, Fabry disease, and other syndromes. This explains why some patients exhibit cardiac, ocular, renal, endocrine, or central neurological manifestations along with neuropathy. [21]

The main group of reasons	Examples
Gene duplications and deletions	PMP22
Point mutations in myelin genes	MPZ, GJB1, EGR2
Axonal genetic defects	MFN2 and others
Defects that increase vulnerability to nerve compression	PMP22 deletion
Amyloidogenic mutations	TTR
Syndromic hereditary diseases	Refsum disease, Fabry disease and others

Source for the table. [22]

Risk factors

For hereditary neuropathy, the main risk factors are family and genetic predisposition. If there are family members with thin shins, foot deformities, weakness in the distal legs, repeated compression palsies, sensory disturbances, or an "unexplainable" gait since childhood, the likelihood of a hereditary cause increases significantly. However, the absence of a known family history does not rule out the diagnosis, as new mutations, very mild forms in relatives, and underrecognition of the disease in previous generations are possible. [23]

The second important risk factor is a specific inheritance pattern. Charcot-Marie-Tooth disease can be inherited in an autosomal dominant, autosomal recessive, or X-linked manner. Neuropathy with susceptibility to compression palsies is usually inherited in an autosomal dominant manner. This has direct implications for families in counseling, pregnancy planning, and screening of relatives. [24]

For some subtypes, there are factors that don't cause the disease but exacerbate its symptoms. In neuropathy with susceptibility to compression palsies, the risk of episodes is increased by prolonged sitting with legs crossed, leaning on the elbows, repetitive wrist movements, rapid weight loss, carrying a heavy backpack, and certain neurotoxic drugs, especially vincristine. These factors are not a genetic risk, but rather factors that decompensate an existing genetic defect. [25]

A separate risk group are patients with a "complex" phenotype, who, in addition to polyneuropathy, have cardiomyopathy, arrhythmia, renal problems, cataracts, hearing loss, optic atrophy, spinal deformity, or motor developmental delay. This combination of features increases the likelihood of a rare syndromic hereditary neuropathy and requires extensive genetic testing. [26]

Modern molecular research adds another practical risk factor for late diagnosis: an overly narrow initial search. A 2024 study using large gene panels showed that limiting diagnostics to only a few "classical" genes can miss a significant proportion of molecular diagnoses and potentially clinically important findings. Therefore, an overly conservative diagnostic strategy is now also becoming a risk factor for error. [27]

Risk factor	Why is it important?
Family history	Increases the likelihood of a hereditary cause
A certain type of inheritance in the family	Affects the risk to children and relatives
New mutation in the patient	Possible even without a family history
Nerve compression and microtrauma in certain subtypes	Enhance clinical manifestations
Narrow genetic diagnostics	Increases the risk of missing an accurate molecular diagnosis

Source for the table. [28]

Pathogenesis

The pathogenesis of hereditary neuropathies depends on which part of the peripheral nerve is damaged first. In demyelinating forms, the primary defect affects the myelin sheath. Myelin is essential for the rapid conduction of electrical impulses, so damage to it leads to a sharp slowdown in nerve conduction, decreased reflexes, weakness, and gradual muscle atrophy. This mechanism is typical for many variants of Charcot-Marie-Tooth disease type 1. [29]

In axonal forms, it's not the sheath that's affected, but the long nerve cell itself, primarily its distal regions. Due to the length of the nerve fibers, the feet and legs are usually affected first, followed by the hands. Therefore, the clinical picture often begins with distal weakness, foot drop, decreased sensitivity similar to toe drop, and gradual involvement of the hands. Electrophysiologically, conduction velocity may be relatively intact, but response amplitude is reduced. [30]

In neuropathy with susceptibility to compression palsies, the pathogenesis is associated with a deficiency of the peripheral myelin protein 22. As a result, myelin becomes structurally less stable, and the nerve is more vulnerable to even moderate external pressure. This is why such patients may develop episodes of local neuropathy after normal posture, sleep, wearing a backpack, or minimal trauma. [31]

In hereditary transthyretin amyloidosis, the mechanism is different: mutant transthyretin forms unstable structures and is deposited as amyloid in the nerves and tissues of various organs. This leads to slowly progressive sensorimotor and autonomic neuropathy, often accompanied by cardiac, ocular, and renal manifestations. In this case, the peripheral nerve is damaged not only by the genetic program but also by the accumulation of pathological protein. [32]

Pathogenesis also explains the phenotypic diversity of the disease. The same gene can produce different patterns depending on the type of mutation, while different genes can produce a similar clinical phenotype. Therefore, the modern language of hereditary neuropathy is moving away from the old, purely clinical terms toward a combination of phenotype, electrophysiology, and molecular cause. [33]

Pathogenesis variant	What suffers first?	Typical result
Demyelinating	Myelin sheath	Marked slowing of nerve conduction
Axonal	Axon	Distal weakness and decreased response amplitude
Compression-vulnerable	Structural stability of myelin	Episodes of mononeuropathy after pressure
Amyloid	Peripheral nerves and organ tissues	Polyneuropathy with systemic manifestations
Syndromic multisystem	Nerves plus other organs	More complex phenotype

Source for the table. [34]

Symptoms

Symptoms of hereditary neuropathy vary by subtype, but the most common are slowly progressive weakness in the feet and legs, frequent inversion of the feet, difficulty running, fatigue when walking, thin legs, and foot deformities. Charcot-Marie-Tooth disease is characterized by foot drop, high arches, hammertoes, and gradual involvement of the hands. Merck also describes decreased vibration, pain, and temperature sensation in a sock-glove pattern, as well as absent tendon reflexes. [35]

Sensory symptoms may include numbness, tingling, burning, and decreased sensitivity to pain and temperature. According to the National Institute of Neurological Disorders and Stroke, hereditary neuropathies, depending on the type, may present with numbness, tingling, and pain in the feet and hands, or motor symptoms with weakness and wasting. These symptoms often develop gradually and may go unrecognized for a long time. [36]

In sensory and vegetative forms, the primary symptoms may not be weakness and foot deformities, but rather decreased pain sensitivity, injuries, ulcers, infections, sweating disorders, orthostatic hypotension, gastrointestinal disorders, urinary disorders, and thermoregulatory disorders. In rare cases, the disease begins in childhood and manifests itself through repeated injuries due to decreased pain sensitivity. [37]

A unique clinical scenario is observed in neuropathy with susceptibility to compression palsies. It is characterized by acute, often painless, episodes of localized weakness or numbness in the area of a single nerve, such as the peroneal, ulnar, or median nerve. Following an episode, recovery is often complete or nearly complete, creating the false impression of a "random" problem and delaying diagnosis. [38]

In hereditary transthyretin amyloidosis, systemic symptoms often occur: weight loss, orthostatic hypotension, constipation alternating with diarrhea, nausea, vomiting, delayed gastric emptying, erectile dysfunction, impaired sweating, and signs of cardiac involvement. It is the combination of polyneuropathy with cardiac, ocular, or renal involvement that should prompt consideration not of "common" Charcot-Marie-Tooth disease, but of a different subtype of hereditary neuropathy. [39]

Group of symptoms	How does it manifest itself?
Motor	Weakness of the feet and legs, foot drop, atrophy, difficulty walking
Sensitive	Numbness, tingling, burning, decreased pain and temperature
Orthopedic	High arches, hammertoes, sometimes scoliosis
Vegetative	Sweating, pressure when standing up, intestinal and urinary disorders
Focal episodes	Repeated compression paralysis in susceptible forms
Systemic signs	Cardiac, ocular, and renal manifestations in amyloid forms

Source for the table. [40]

Classification, forms and stages

The modern classification of hereditary neuropathies is based on three main axes: the type of affected fiber, the electrophysiological pattern, and the mode of inheritance. The simplest basic division is into motor-sensory, sensory and autonomic, and predominantly motor forms. This is the general classification used by Merck. [41]

Within the motor-sensory forms, the most important division is into demyelinating, axonal, and intermediate variants. The International Classification of Diseases, 11th revision, and GeneReviews reflect this using Charcot-Marie-Tooth disease as an example, where demyelinating, axonal, and intermediate forms are distinguished separately. This division is not a formality: it helps select the correct genetic strategy and accurately interpret electromyography and nerve conduction study data. [42]

According to the mode of inheritance, the forms can be autosomal dominant, autosomal recessive, and X-linked. This is especially important for genetic counseling. For example, Charcot-Marie-Tooth disease as a phenotypic group can be inherited by all three pathways, whereas neuropathy with susceptibility to compression palsies is usually autosomal dominant. [43]

Based on the age of onset, the disease is classified into congenital, childhood, adolescent, and adult forms. Merck emphasizes that many classic forms begin in childhood, but the severity and rate of progression vary greatly. This is why staging in hereditary neuropathy is often clinical and functional in nature, rather than a universal, formal approach, as is the case, for example, with cancer. [44]

From a practical standpoint, it is convenient to distinguish between mild, moderate, and severe functional stages. In the mild stage, clumsiness, foot deformities, and decreased reflexes predominate. In the moderate stage, persistent weakness, the need for orthoses, and limitations in walking and hand function develop. In the severe stage, the use of a cane, walker, or wheelchair may be possible, and in some syndromic forms, severe autonomic and systemic complications are added. Current recommendations emphasize functional assessment, as it directly influences rehabilitation and orthopedic treatment. [45]

Classification principle	Options
By type of lesion	Motor-sensory, sensory and vegetative, motor
On electrophysiology	Demyelinating, axonal, intermediate
By inheritance	Autosomal dominant, autosomal recessive, X-linked
By age of debut	Congenital, childhood, adolescent, adult
By functional severity	Mild, moderate, severe stage

Source for the table. [46]

Complications and consequences

Complications of hereditary neuropathy accumulate slowly but can seriously impact quality of life. The most common consequences include foot deformities, ankle instability, falls, decreased walking speed, fatigue, and limited hand function. If the disease progresses over years, persistent distal muscle atrophy develops and independence in daily life decreases. [47]

In sensory and autonomic forms, complications can be more devastating than the weakness itself. Decreased pain sensitivity can lead to unnoticed injuries, ulcers, infections, foot deformities, and even osteomyelitis. Merck explicitly emphasizes that the risk of foot damage is particularly high in rare hereditary sensory and autonomic neuropathies. [48]

Some patients develop scoliosis, contractures, chronic neuropathic pain, sleep disturbances, and anxiety-depressive reactions associated with activity limitations. Even if the disease progresses slowly, it can interfere with education, work, sports activities, and independence in everyday life. This is important because hereditary neuropathy is often perceived as "slow and therefore harmless," although the functional impairment can be significant. [49]

For certain subtypes, complications extend beyond the peripheral nerves. In hereditary transthyretin amyloidosis, cardiomyopathy, conduction disturbances, and damage to the kidneys, eyes, and central nervous system are possible. In such cases, the prognosis and complication profile are determined not only by the polyneuropathy but also by the systemic nature of the process. [50]

In neuropathy with susceptibility to compression palsies, the main complication is repeated episodes of local neuropathy, which can lead to cumulative deficits, especially if the underlying factors are not corrected. Therefore, even "mild" hereditary neuropathy requires monitoring and patient education. [51]

Complication	Why does it arise?
Foot deformities	Chronic muscle imbalance
Falls and instability	Weakness of the feet and impaired sensitivity
Foot ulcers and infections	Loss of pain sensitivity
Contractures and limited mobility	Long-term disruption of biomechanics
Neuropathic pain	Chronic nerve damage
Systemic complications	Characteristic of amyloid and syndromic forms

Source for the table. [52]

When to see a doctor

You should always consult a doctor if you experience slowly progressing weakness in your feet, frequent ankle twisting, foot deformities, difficulty running or rising on your toes, unusually thin shins, or a combination of these symptoms in several family members. Early consultation is especially important for children and adolescents.

You should always consult a doctor if you experience slowly increasing weakness in your feet, frequent ankle twisting, foot deformities, difficulty running or rising on your toes, unusually thin shins, or a combination of these symptoms in several family members. Early consultation is especially important for children and adolescents, as it is at this age that it is easier to begin orthotics, rehabilitation, and prevention of secondary deformities. [53]

Not only motor symptoms, but also persistent numbness, burning pain, decreased sensitivity to pain and temperature, repeated foot injuries, ulcers, sweating disorders, dizziness upon standing, unexplained intestinal disorders, and urinary problems warrant a more rapid examination. This combination of symptoms may indicate a sensory or vegetative form, which requires a different diagnostic approach. [54]

Urgent consultation is especially important if a person experiences repeated episodes of sudden weakness of the hand, foot, or individual muscles following minor nerve pressure, awkward posture, or physical activity. This is typical for neuropathy with a predisposition to compression palsies, and timely recognition can prevent further episodes. [55]

Certain red flags include polyneuropathy combined with cardiac symptoms, arrhythmia, severe orthostatic hypotension, weight loss, diarrhea or constipation, ocular symptoms, a family history of sudden death, or systemic amyloidosis. In such cases, hereditary transthyretin amyloidosis and other complex hereditary syndromes must be excluded. [56]

Even if symptoms are mild, a consultation with a neurologist is warranted when the family already knows the genetic diagnosis. This allows for the possibility of developing a monitoring plan, assessing relatives, and discussing reproductive risks rather than waiting for significant disability. [57]

Situation	Why do you need a doctor?
Weakness of the feet and frequent twisting	Early onset of the motor-sensory form is possible
Foot deformities in several relatives	Suspected hereditary phenotype
Numbness, pain, loss of sensation	The type of neuropathy needs to be clarified.
Recurrent mononeuropathies after pressure	It is necessary to exclude susceptibility to compression palsy.
Polyneuropathy plus cardiac and autonomic symptoms	The amyloid form must be excluded.

Source for the table. [58]

Diagnostics

Diagnosis of hereditary neuropathy begins with a clinical assessment rather than a single laboratory test. The physician considers the age of onset, slow progression, family history, the distribution of weakness, the presence of foot deformities, thin shins, decreased reflexes, sensory disturbances, and autonomic symptoms. Current guidelines emphasize that suspicion of Charcot-Marie-Tooth disease and related forms is primarily clinical. [59]

The next step is electrophysiology, which includes electromyography and nerve conduction studies. These methods help determine whether the process is demyelinating, axonal, or mixed. For hereditary neuropathies, this is critical, as the electrophysiological type helps narrow down the genes involved and distinguish the hereditary form from some acquired polyneuropathies. Merck specifically states that the characteristic distribution of weakness, foot deformities, and family history should be confirmed by electrodiagnostic testing. [60]

After this, molecular confirmation is crucial. GeneReviews recommends collecting a detailed family history for at least three generations and using molecular genetic testing for Charcot-Marie-Tooth disease. This approach may include targeted analysis of known genes, a multigene panel, or exome or genome sequencing. In modern practice, the combination of phenotype, electrophysiology, and genetics is considered the gold standard for accurate diagnosis. [61]

There is a diagnostic algorithm for neuropathy with susceptibility to compression palsies. In cases of characteristic recurrent mononeuropathies, an electrophysiological study is typically performed first, followed by a targeted search for deletions or other pathogenic variants in the PMP22 gene. GeneReviews indicates that approximately 80% of cases are associated with deletions, and approximately 20% with other pathogenic variants of this gene. [62]

If hereditary transthyretin amyloidosis is suspected, the route is different. Here, it is important not only to confirm the TTR gene mutation but also to assess the involvement of the heart, eyes, kidneys, and autonomic nervous system. Therefore, diagnosis is multidisciplinary: neurological, cardiological, ophthalmological, and sometimes gastrointestinal. [63]

Additional tests are used on a case-by-case basis. Nerve biopsy is needed significantly less frequently today than in the past, as genetics and modern electrophysiological data often make it possible to avoid invasive methods. However, in certain cases, particularly with complex or unclear phenotypes, biopsy, magnetic resonance imaging of the nerves, or ultrasound imaging of the nerves can still provide a complete picture. Characteristic changes in ultrasound and magnetic resonance imaging of the nerves have been described for neuropathy with susceptibility to compression palsies. [64]

The current trend is to expand genetic testing beyond the scope of a few well-known genes. A 2024 study on a large cohort of adult patients showed that multigene panels identified molecular diagnoses in a subset of patients who might otherwise have been missed by previous testing guidelines. This is important not only for disease naming, but also for assessing familial risk, prognosis, and treatment selection in rare but potentially targetable forms. [65]

Diagnostic step	What does it give?
Clinical examination	Allows one to suspect a hereditary phenotype
Family history	Helps to see the type of inheritance
Electromyography and nerve conduction studies	A distinction is made between demyelinating and axonal variants.
Genetic testing	Confirms an accurate molecular diagnosis
Additional imaging or biopsy	Used in complex and controversial cases
Interdisciplinary examination	It is necessary for systemic forms, especially amyloid ones.

Source for the table. [66]

Differential diagnosis

Hereditary neuropathy must first be distinguished from acquired polyneuropathies. In everyday practice, these include diabetic polyneuropathy, chronic inflammatory demyelinating polyradiculoneuropathy, alcoholic neuropathy, vitamin deficiency, toxic nerve damage, and paraneoplastic processes. Slow onset, a family history, foot deformities, long-term stable progression, and characteristic electrophysiological signs usually support the hereditary form. [67]

Hereditary demyelinating forms are particularly important to distinguish from chronic inflammatory demyelinating polyradiculoneuropathy. Mistakes here can lead to unnecessary treatment with immunoglobulins or glucocorticoids. The hereditary form often has a longer history, orthopedic deformities, a familial history, and less pronounced symptom fluctuation, although the boundaries are sometimes blurred and some patients require complex expert evaluation. [68]

In focal episodic palsies, differential diagnosis must be made between neuropathies with susceptibility to compression palsies, common tunnel syndromes, traumatic neuropathies, and inflammatory mononeuropathies. The recurrence of episodes, their relationship to compression, family history, and findings from electrophysiology and genetic testing enable the correct diagnosis to be made. [69]

If polyneuropathy is accompanied by cardiomyopathy, conduction disturbances, pronounced autonomic symptoms, weight loss, and ocular or renal manifestations, hereditary transthyretin amyloidosis must be distinguished from other amyloidoses and multisystem diseases. Here, the cost of error is particularly high, because it is for this form that targeted treatment options are available, and early diagnosis can significantly change the prognosis. [70]

In pediatric practice, the differential diagnosis includes hereditary muscle diseases, spinal muscular atrophies, mild cerebral palsy, congenital myopathies, and orthopedic causes of foot deformities. Therefore, the diagnosis of hereditary neuropathy is almost always a collaborative effort between a neurologist, neurophysiologist, geneticist, and rehabilitation specialist. [71]

What is it compared to?	What helps to distinguish
Diabetic and toxic polyneuropathy	Family history, early onset, foot deformities
Chronic inflammatory demyelinating polyradiculoneuropathy	Duration, heredity, genetics, orthopedic signs
Tunnel syndromes	Recurrent episodes and familial history in patients with compression palsies
Muscle diseases	Electromyography and deficit distribution pattern
Amyloidosis and syndromic diseases	Genetics plus systemic manifestations

Source for the table. [72]

Treatment

Treatment of hereditary neuropathy remains supportive in most cases, but modern approaches no longer limit themselves to the phrase "nothing can be done." The primary goals are to preserve function for as long as possible, prevent secondary deformities, reduce pain, support walking and manual activity, promptly correct orthopedic problems, and not miss subtypes for which more precise therapy exists. The 2024-2025 guidelines for Charcot-Marie-Tooth disease emphasize that patients should be monitored by a multidisciplinary team, and rehabilitation and orthopedic measures should be initiated early. [73]

The first line of treatment is physical and functional rehabilitation. This is not simply "physical therapy," but an individually tailored program aimed at maintaining range of motion, strength, balance, endurance, and a safe gait. Current guidelines for Charcot-Marie-Tooth disease emphasize that exercises should be personalized, as excessive loading and random, one-size-fits-all programs may be less beneficial than a structured program tailored to a specific phenotype. [74]

The second approach is orthotics. Ankle-foot orthoses are widely used for foot drop and distal weakness, while splints and other supporting devices are used for hand weakness and localized deficits. Merck specifically states that orthoses help compensate for foot drop, and for certain subtypes, particularly neuropathy with susceptibility to compression palsies, they can be used temporarily or permanently, depending on the severity of the deficit. [75]

The third approach is orthopedic surgery for severe deformities. In hereditary neuropathies, this does not treat the underlying cause of the disease, but can significantly improve foot biomechanics, stability, and walking ability. Current guidelines for Charcot-Marie-Tooth disease recommend conservative and reconstructive approaches, including tendon rerouting and function-preserving surgeries, rather than "mutilating" late surgeries. The decision is always individualized and depends on the type of deformity and residual muscle strength. [76]

The fourth area is pain management. Not all patients experience the same level of pain, but in axonal, sensory, and amyloid forms, neuropathic pain can be significant. For hereditary transthyretin amyloidosis, GeneReviews lists serotonin-norepinephrine reuptake inhibitors, gabapentin, pregabalin, weak opioid analgesics, and topical agents such as lidocaine and capsaicin for symptomatic pain control. More broadly, these same principles apply to other hereditary neuropathies if neuropathic pain is present. [77]

The fifth area is preventing secondary damage. For sensory and vegetative forms, this is critical, as pain loss increases the risk of ulcers, infections, and osteomyelitis. In such cases, treatment includes regular foot examinations, proper footwear selection, pressure relief, patient and family education, early treatment of any wounds, and sometimes special off-loading devices. For neuropathy with a tendency toward compression palsies, protective elbow and knee pads, correct body positioning, and avoiding habits that put pressure on the nerve are additionally important. [78]

The sixth area is lifestyle modification and avoidance of triggers for certain subtypes. For neuropathy with susceptibility to compression palsies, GeneReviews recommends avoiding prolonged sitting with legs crossed, prolonged elbow support, repetitive wrist strain, rapid weight loss, and vincristine. This is a good example of how knowing the exact genetic subtype changes lifestyle recommendations and can actually reduce the incidence of new episodes. [79]

The seventh area is genetic counseling and family support. From a practical standpoint, this is also part of treatment, as it helps families understand the risk to relatives, correctly interpret mild symptoms in children and adults, promptly screen those with subclinical disease, and discuss reproductive decisions. GeneReviews on Charcot-Marie-Tooth disease specifically emphasizes the role of accurate molecular diagnosis in assessing family risk. [80]

The eighth area is targeted therapy for hereditary transthyretin amyloidosis. This is one of the major advances in recent years in the field of hereditary neuropathies. GeneReviews 2024 indicates that the first-line treatment for this form is pharmacological methods aimed at suppressing the synthesis of pathological transthyretin or stabilizing its tetramer. For peripheral neuropathy, gene-targeted drugs such as patisiran, vutriseran, inotersen, and eplontersen are used, as well as transthyretin stabilizers, including tafamidis and, in certain situations, diflunisal. [81]

The ninth area is the choice of therapy for amyloidosis based on phenotype. GeneReviews highlights that in the pure neuropathic form, gene-suppressing agents, particularly vutriceran and eplontersen, are increasingly preferred, while liver transplantation is no longer considered first-line therapy. This is a significant shift, as it represents a shift away from older organ-replacement strategies toward more precise molecular interventions. [82]

The tenth area is new methods for Charcot-Marie-Tooth disease and related forms. Currently, there is no standard, registered disease-modifying drug for most variants of Charcot-Marie-Tooth disease, which is directly reflected in the 2025 clinical guidelines. However, research is advancing rapidly. The 2025 reviews discuss approaches to reducing the dose of PMP22, small molecules such as PXT3003, gene therapy, and gene silencing platforms. Furthermore, according to Novartis, a phase 1 study of EDK060 in adults with Charcot-Marie-Tooth disease type 1A began in 2025. This is still an experimental stage, and such methods cannot be presented as a standard of care, but they are shaping the near future of therapy. [83]

The eleventh area is surveillance. For Charcot-Marie-Tooth disease, the 2025 guidelines emphasize that routine follow-up care is primarily clinical, without mandatory, ongoing, repeated instrumentation unless specifically indicated. For hereditary transthyretin amyloidosis, GeneReviews recommends regular monitoring of existing manifestations and the development of new ones, as the disease affects multiple organ systems. In other words, even where curative treatment is not available, proper surveillance is an active, not a passive, tactic. [84]

Treatment approach	Role
Rehabilitation	Maintains walking, balance and hand function
Orthotics	Compensates for foot drop and local deficiencies
Orthopedic surgery	Corrects pronounced deformations
Treatment of neuropathic pain	Improves quality of life
Prevention of ulcers and injuries	Especially important for sensory forms
Avoiding nerve compression	Critical for those susceptible to compression palsies
Genetic counseling	Impact on family and early detection
Targeted therapy for amyloidosis	May slow the progression of neuropathy
Experimental methods for Charcot-Marie-Tooth disease	They are still being studied, but are developing rapidly.

Source for the table. [85]

Prevention

There is no primary prevention that would prevent the genetic defect itself. However, secondary prevention of complications and functional deterioration plays a huge role. This includes early diagnosis, proper footwear, orthotics as indicated, regular exercise, deformity control, and foot protection from chronic injury. [86]

For neuropathy with susceptibility to compression palsies, prevention is particularly specific and practical. Avoiding prolonged nerve compression, sudden weight loss, repeated hand strain, and neurotoxic medications, particularly vincristine, is essential. It is also helpful for patients to discuss the risks of lengthy surgeries and awkward body positions during medical procedures. [87]

For sensory forms, the main prevention consists of protecting the feet and regularly inspecting the skin. Even a small wound with impaired sensitivity can go unnoticed and lead to infection. Therefore, patient and family education is practically equivalent to drug prophylaxis. [88]

Family prevention includes genetic counseling, identification of at-risk relatives, and discussion of prenatal or preimplantation genetic testing in families with a known pathogenic variant. GeneReviews emphasizes that such decisions should be made after accurate molecular confirmation and professional counseling. [89]

Preventive measure	What is it for?
Early detection	Allows to begin rehabilitation before severe deformation occurs
Foot protection and proper footwear	Reduces the risk of ulcers and falls
Avoiding nerve compression	Prevents episodes in susceptible forms
Genetic counseling	Helps families assess risks
Regular monitoring	Allows you to adjust tactics in time

Source for the table. [90]

Forecast

The prognosis for hereditary neuropathy depends on the subtype of the disease. Many classic forms of Charcot-Marie-Tooth disease are characterized by slow progression over decades. Merck notes that in typical variants, the disease progresses slowly and usually does not shorten life expectancy, although the degree of functional limitation can be significant. [91]

The functional prognosis is largely determined by the age of onset, the degree of axonal damage, the presence of orthopedic deformities, and the rate of hand involvement. Even with favorable survival, the disease can significantly limit walking, daily independence, and professional activity, so the prognosis should always be described not only in terms of "life" and "death," but also in terms of quality of life. [92]

In neuropathies susceptible to compression palsies, the prognosis is often relatively benign. Acute episodes often recover completely, and if recovery is incomplete, residual deficits are usually moderate. However, with repeated compressions and the absence of preventive measures, functional losses can accumulate. [93]

For hereditary transthyretin amyloidosis, the prognosis has changed dramatically thanks to targeted therapy. Early diagnosis and timely initiation of gene-directed treatment or transthyretin stabilizers can slow the progression of neuropathy and improve outcomes. Therefore, the prognosis for this form is closely linked to the timing of disease recognition. [94]

Subtype or situation	General forecast
Classic Charcot-Marie-Tooth disease	Slowly progressive, often without shortening life
Early, difficult debut	More pronounced functional loss
Neuropathy with susceptibility to compression palsies	Often relatively mild, but with a risk of recurrent episodes
Sensory and vegetative forms	Dependent on injuries, ulcers and autonomic complications
Hereditary transthyretin amyloidosis	Improves with early targeted therapy

Source for the table. [95]

FAQ

What is most often meant by hereditary neuropathy?
Most often, this refers to Charcot-Marie-Tooth disease and related hereditary motor-sensory forms, but in practice, this term covers a much broader group of diseases. [96]

Does hereditary neuropathy always begin in childhood?
No. Many forms do begin in childhood or adolescence, but some variants may begin in adulthood, and milder forms are sometimes recognized very late. [97]

Can a diagnosis be made solely by electromyography?
No. Electrophysiology is extremely important, but today, it is advisable to confirm an accurate diagnosis with molecular genetic testing, especially if it affects the family prognosis or the choice of targeted therapy. [98]

Is hereditary neuropathy curable?
For most forms, there is no complete cure, and treatment remains supportive. However, targeted drugs are already available for hereditary transthyretin amyloidosis, which have significantly changed the approach to disease management. [99]

Is it possible to miss hereditary neuropathy if no one in the family has it?
Yes. The cause could be mild, unrecognized forms in relatives, new mutations, or a family misinterpretation of the disease as "leg peculiarities" or "weak feet." [100]

Do relatives need testing if the diagnosis has already been confirmed in one family member?
In many cases, yes, because it helps identify mild forms, assess the risk to offspring, and provide timely recommendations for preventing complications. [101]

Key points from experts

Thomas D. Bird, MD, Seattle VA Medical Center and University of Washington, emphasizes in GeneReviews 2025 that Charcot-Marie-Tooth disease is not a single entity but a broad spectrum of chronic motor-sensory polyneuropathies. His main practical point is that clinical evaluation should be combined with a detailed family history and molecular testing, because without genetic confirmation, the exact subtype often remains unclear. [102]

Michael Rubin, MD, PhD, New York-Presbyterian Hospital-Cornell Medical Center, emphasizes clinical recognition in the professional version of the Merck Manual. He emphasizes the importance of typical weakness distribution, foot deformities, family history, electrodiagnostics, and supportive treatment with orthoses, physical therapy, and, if necessary, orthopedic surgery. [103]

Nicolas Chrestian, MD, FRCPSC, FCCS, demonstrates the importance of proper lifestyle recommendations in his GeneReviews article on neuropathy with susceptibility to compression palsies. His review is particularly valuable because it translates genetic diagnosis into practical advice: how to reduce nerve compression, what positions and situations to avoid, and why even mild, recurrent episodes of local weakness should not be underestimated in these patients. [104]

Yoshiki Sekijima, MD, PhD, and Katsuya Nakamura, MD, PhD, of Shinshu University School of Medicine, in their GeneReviews 2024 paper on hereditary transthyretin amyloidosis, effectively articulate the central thesis of the entire topic: some hereditary neuropathies have already transitioned from the era of solely symptomatic care to the era of targeted therapy. Their review emphasizes that early recognition of the amyloid form allows for the use of drugs aimed at suppressing pathological transthyretin, thereby altering the natural course of the disease. [105]

Conclusion

Hereditary neuropathy is a large and heterogeneous group of diseases united by peripheral nerve damage, but differing in genes, mechanism, age of onset, rate of progression, and prognosis. Clinically, it can present with weakness of the feet and hands, deformities, sensory disturbances, neuropathic pain, recurrent compression palsies, or systemic manifestations in complex syndromic variants. [106]

The main change of recent years is the transition from descriptive diagnostics to precise molecular diagnostics. For patients, this means a more accurate understanding of the causes of the disease, an accurate prognosis for the family, and, in some cases, access to targeted therapy. By 2026, hereditary neuropathy will no longer be perceived as a condition for observation alone. Even if a curative cure is not yet available, early rehabilitation, orthotics, orthopedic correction, complication prevention, and competent genetic monitoring can significantly improve quality of life. [107]